Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 267

1.
2.

Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.

Chang ST, Tenforde AS, Grimsrud CD, O'Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC.

Bone. 2012 Sep;51(3):524-7. doi: 10.1016/j.bone.2012.05.010. Epub 2012 May 23.

PMID:
22634175
[PubMed - indexed for MEDLINE]
3.

The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.

Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ.

Urology. 2010 May;75(5):1138-43. doi: 10.1016/j.urology.2009.11.083. Epub 2010 Mar 19.

PMID:
20303574
[PubMed - indexed for MEDLINE]
4.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
[PubMed - indexed for MEDLINE]
5.

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.

Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35. Epub 2013 Oct 1.

PMID:
24080992
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer.

Kishimoto Y, Iwase T, Koyama A, Masui T, Yoshida G, Matsuo H, Ishiguro N.

Nagoya J Med Sci. 2011 Aug;73(3-4):211-5.

PMID:
21928703
[PubMed - indexed for MEDLINE]
7.

The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years.

Haschka J, K├╝hne F, Muschitz C, Pirker T, Kocijan R, Bittighofer C, Trubrich A, Resch H.

Wien Klin Wochenschr. 2011 Nov;123(21-22):684-7. doi: 10.1007/s00508-011-0034-8. Epub 2011 Aug 15.

PMID:
21837437
[PubMed - indexed for MEDLINE]
8.

Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails.

Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC.

Clin Orthop Relat Res. 2014 Sep;472(9):2728-34. doi: 10.1007/s11999-013-2963-1.

PMID:
23604648
[PubMed - indexed for MEDLINE]
9.

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Nieves JW, Cosman F.

Curr Osteoporos Rep. 2010 Mar;8(1):34-9. doi: 10.1007/s11914-010-0007-2. Review.

PMID:
20425089
[PubMed - indexed for MEDLINE]
10.

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.

Higano CS.

Urol Clin North Am. 2004 May;31(2):331-52. Review.

PMID:
15123412
[PubMed - indexed for MEDLINE]
11.

Treatment of femoral fracture nonunion after long-term bisphosphonate use.

Grady MK, Watson JT, Cannada LK.

Orthopedics. 2012 Jun;35(6):e991-5. doi: 10.3928/01477447-20120525-51.

PMID:
22691683
[PubMed - indexed for MEDLINE]
12.

The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.

Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ.

J Trauma. 2011 Jul;71(1):186-90. doi: 10.1097/TA.0b013e31821957e3.

PMID:
21610533
[PubMed - indexed for MEDLINE]
13.

Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer.

Yee CH, Ng CF, Wong AY, Chan CK, Hou SM, Yip SK.

Asia Pac J Clin Oncol. 2011 Jun;7(2):168-73. doi: 10.1111/j.1743-7563.2011.01388.x.

PMID:
21585697
[PubMed - indexed for MEDLINE]
14.

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.

J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046. Epub 2009 Sep 16.

PMID:
19758618
[PubMed - indexed for MEDLINE]
15.

Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG.

Clin Orthop Relat Res. 2012 Aug;470(8):2295-301. doi: 10.1007/s11999-012-2412-6. Epub 2012 Jun 6.

PMID:
22669553
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed!

Rydholm A.

Acta Orthop. 2012 Aug;83(4):319-20. doi: 10.3109/17453674.2012.718517. Epub 2012 Aug 20. No abstract available.

PMID:
22900912
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.

Wadhwa VK, Weston R, Parr NJ.

BJU Int. 2010 Apr;105(8):1082-8. doi: 10.1111/j.1464-410X.2009.08956.x. Epub 2009 Nov 13.

PMID:
19912210
[PubMed - indexed for MEDLINE]
18.

Atraumatic bilateral femur fracture in long-term bisphosphonate use.

Goddard MS, Reid KR, Johnston JC, Khanuja HS.

Orthopedics. 2009 Aug;32(8). pii: orthosupersite.com/view.asp?rID=41933. doi: 10.3928/01477447-20090624-27. Review.

PMID:
19708622
[PubMed - indexed for MEDLINE]
19.

Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.

Doggrell SA.

Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8. doi: 10.1586/era.09.95. Review.

PMID:
19761424
[PubMed - indexed for MEDLINE]
20.

Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.

Patel VC, Lazzarini AM.

Orthopedics. 2010 Oct 11;33(10):775. doi: 10.3928/01477447-20100826-31.

PMID:
20954650
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk